RAPT - RAPT Therpaeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

495.1M

Cash

231.6M

Avg Qtr Burn

-18.45M

Short % of Float

11.53%

Insider Ownership

1.91%

Institutional Own.

97.60%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RPT193 (CCR4 antagonist) Details Atopic dermatitis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FLX475 (CCR4 antagonist) Details Solid tumor/s, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RPT193 (CCR4 antagonist) Details Asthma, Lung disease	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.